Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)

This study is currently recruiting participants.
Verified February 2013 by Polynoma LLC
Sponsor:
Information provided by (Responsible Party):
Polynoma LLC
ClinicalTrials.gov Identifier:
NCT01546571
First received: February 26, 2012
Last updated: February 13, 2013
Last verified: February 2013
  Purpose

The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.


Condition Intervention Phase
Melanoma
Biological: POL-103A
Biological: POL-103A without API
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Resource links provided by NLM:


Further study details as provided by Polynoma LLC:

Primary Outcome Measures:
  • Recurrence Free Survival (RFS) [ Time Frame: 362 events ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 472 events ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 1059
Study Start Date: April 2012
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: POL-103A without API Biological: POL-103A without API
Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
Experimental: POL-103A Biological: POL-103A
POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed Stage IIb, IIc, III melanoma
  • Surgical resection within 90 days of first dosing
  • Persons with positive sentinel nodes must have a complete lymphadenectomy
  • ECOG performance status 0 or 1

Exclusion Criteria:

  • Any prior melanoma treatment other than surgery or regional irradiation
  • Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin
  • Use of biologic response modifiers within 60 days of first dosing
  • Subjects with history of other malignancy within past 5 years (with exceptions)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01546571

Contacts
Contact: Deb Jezior (858) 254-8480 debjezior@polynoma.com
Contact: Patrick Mallon (858) 205-2501 pmallon@polynoma.com

  Hide Study Locations
Locations
United States, Arizona
University of Arizona Cancer Center Recruiting
Tucson, Arizona, United States, 85719
Contact: Susan Jordan, BS.,CCRC     520-694-9056        
Principal Investigator: Lee Cranmer, MD            
Arizona Clinical Research Recruiting
Tucson, Arizona, United States, 85715
Contact: Patricia Plezia, Ph.D.     520-290-2510        
Principal Investigator: Manuel Modiano, MD            
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Cindy Witkowski     501-526-6990 ext 8026        
Principal Investigator: Laura Hutchins, MD            
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
Contact: Raechelle Tinsley     626-256-4673 ext 63015        
Principal Investigator: Sanjay Awasthi, MD            
The Angeles Clinic and Research Institute Recruiting
Los Angeles, California, United States, 90025
Contact: Saba Mukarram     310-582-7900        
Principal Investigator: Omid Hamid, MD            
Northern California Melanoma Center/ St. Mary's Medical Center Recruiting
San Francisco, California, United States, 94117
Contact: Lonnie Leonard     415-750-4060        
Principal Investigator: Lynn Spitler, MD            
Pacific Dermatology Institute Recruiting
Temecula, California, United States, 92592
Contact: Ashley Brook     951-303-6900        
Principal Investigator: Jesse Mitchell, MD            
United States, Colorado
Anschutz Cancer Pavilion Recruiting
Aurora, Colorado, United States, 80045
Contact: Barb Criminelli     720-848-0652        
Principal Investigator: Karl Lewis, MD            
United States, District of Columbia
The Melanoma Center at the Washington Cancer Institute Recruiting
Washington, District of Columbia, United States, 20010
Contact: Chris Mathew     202-877-5371        
Principal Investigator: Sekwon Jang, MD            
United States, Florida
Mount Sinai Medical Center Recruiting
Miami Beach, Florida, United States, 33140
Contact: Yvonne Enriquez-Nunez     305-674-2625        
Principal Investigator: Jose Lutzky, MD            
MD Anderson Cancer Center-Orlando Recruiting
Orlando, Florida, United States, 32806
Contact: Jean Edwards     321-841-6653        
Principal Investigator: Gregory Pennock, MD            
Ameriderm Research Recruiting
Ormond Beach, Florida, United States, 32174
Contact: Jody Wheeler     386-898-0547        
Principal Investigator: James Solomon, MD            
United States, Illinois
Oncology Specialists, SC (OSSC) Recruiting
Niles, Illinois, United States, 60714
Contact: Sara Edwards     847-410-0658        
Principal Investigator: Sigrun Hallmeyer, MD            
United States, Indiana
Investigative Clinical Research of Indiana Recruiting
Indianapolis, Indiana, United States, 46254
Contact: Leslie Weitman     317-297-2208        
Principal Investigator: Stephen Schultz, MD            
United States, Iowa
University of Iowa Hospitals and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Contact: Melanie Frees     319-353-7251        
Principal Investigator: Mohammed Milhem, MD            
United States, Kentucky
Central Kentucky Research Associates Recruiting
Lexington, Kentucky, United States, 40509
Contact: Susan Lanthorn     859-977-7144        
Principal Investigator: James Borders, MD            
Central Baptist Hospital Recruiting
Lexington, Kentucky, United States, 40503
Contact: Heather Tudor     859-260-3196        
Principal Investigator: Peter Tate, MD            
United States, Minnesota
University of Minnesota Masonic Cancer Institute Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Kathy Evans     612-626-3369        
Principal Investigator: Venkatesh Rudrapatna, MD            
Mayo Clinic Cancer Center, Mayo Clinic Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Jane Milburn     507-266-0743        
Principal Investigator: Svetomir Markovic, MD, PhD            
United States, Missouri
Center for Pharmaceutical Research Recruiting
Kansas City, Missouri, United States, 64114
Contact: Missy MacPhail     816-943-0770        
Principal Investigator: John Ervin, MD            
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Chloe Fournier     314-747-4235        
Principal Investigator: Gerald Linette, MD            
St. Louis Hospital Recruiting
St. Louis, Missouri, United States, 63110
Contact: Kathryn Lindsay     314-577-8460        
Principal Investigator: Eddy Hsueh            
United States, New Hampshire
Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Eryn Bagley     603-650-4035        
Principal Investigator: Marc Ernstoff, MD            
United States, New Jersey
John Theurer Cancer Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Danielle Blair, RN, BSN, OCN     201-996-5809        
Principal Investigator: Andrew Pecora, MD            
Cancer Center of NJ Recruiting
New Brunswick, New Jersey, United States, 08901
Contact: Lori Pruski-Clark     732-235-9835        
Principal Investigator: Janice Mehnert, MD            
United States, New York
Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10032
Contact: Debbie Lehrer     212-824-7376        
Principal Investigator: Yvonne Saenger, MD            
United States, North Carolina
Wake Research Associates Recruiting
Raleigh, North Carolina, United States, 27612
Contact: Tansy Olio     919-781-2514        
Principal Investigator: Adrian Nasir, MD            
Wake Forest University School of Medicine, Comprehensive Cancer Center Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Joyce Fenstermaker, RN     336-713-3155        
Principal Investigator: Edward Levine, MD            
United States, Pennsylvania
Kimmel Cancer Center at Thomas Jefferson Univ. Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Mary Ann Laudadio     215-955-9980        
Principal Investigator: Kendra Feeney, MD            
United States, Texas
Research Across America Recruiting
Dallas, Texas, United States, 75234
Contact: Enrique Echaniz            
Contact     972 492 6990 ext 135        
Principal Investigator: Jeffrey Adelglass, MD            
Dallas Surgical Group Recruiting
Dallas, Texas, United States, 75230
Contact: Tiffany Huber     972-566-4143        
Principal Investigator: Peter Beitsch, MD            
United States, Utah
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84107
Contact: Tricia Fullmer     801-408-3887        
Principal Investigator: Tawnya Bowles, MD            
The Huntsman Cancer Institute, University of Utah Recruiting
Salt Lake City, Utah, United States, 84112-5550
Contact: Jennifer Demko     801-587-4342        
Principal Investigator: Robert Andtbacka, MD            
United States, Virginia
University of Virginia Hospital Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Sasha White     434-982-1902        
Principal Investigator: Craig Slingluff, MD            
Clinical Research Associates of Tidewater Recruiting
Norfolk, Virginia, United States, 23507
Contact: Edith Wombolt     757-627-7446        
Principal Investigator: Duane Wombolt, MD            
Sponsors and Collaborators
Polynoma LLC
Investigators
Principal Investigator: Craig Slingluff, M.D. Martha Jefferson Hospital, University of Virginia
  More Information

No publications provided

Responsible Party: Polynoma LLC
ClinicalTrials.gov Identifier: NCT01546571     History of Changes
Other Study ID Numbers: 103A-301
Study First Received: February 26, 2012
Last Updated: February 13, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on May 23, 2013